A study led by Dr. Michael Poledniczek at the Medical University of Vienna analyzed the relationship between six-minute walk distance (6MWD) and all-cause mortality in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Patients walking less than 350 meters had higher mortality rates, indicated by hazard ratios of 3.29 and 2.30 at baseline, and 5.52 and 2.91 at one year. The study, which included 252 patients, concluded that baseline 6MWD is a crucial prognostic marker in ATTR-CM, with changes in walking distance being less reliable for assessing prognosis following treatment adjustments.

Source: Frontiers in Medicine